Uveal melanoma (UM) is the most commonly diagnosed primary intraocular tumor in adults. Familial UM (FUM), defined as two or more family members diagnosed with UM, is rare and estimated at less than 1% of all UM. Currently, BAP1 is the only gene known to contribute significant risk for UM. In this study we aimed to estimate the frequency of BAP1 mutation in FUM and to characterize the family and personal histories of other cancers in these families. We identified 32 families with FUM, including seven families previously reported by our group. BAP1 mutation testing was carried out by direct sequencing of the coding exons and the adjacent untranslated regions of the gene. Germline deletion and duplication analysis of BAP1 was assessed by multiplex ligation-dependent probe amplification (MLPA). Germline BAP1 mutations were found in 6/32 (19%) families. No deletions or duplications were identified in any of the 24 samples tested by MLPA. Combined with published studies, the frequency of BAP1 mutations was 14/64 (22%) in FUM. FUM families without BAP1 mutations have distinct family histories with high rates of prostate cancer in first-and second-degree relatives. It is likely that additional genes conferring risk for FUM exist. It is important to understand key shared features of FUM to focus future research on identifying these additional tumor predisposition syndromes. Though BAP1 should be tested first in these families, FUM families without BAP1 mutation should be explored for additional predisposition genes.
INTRODUCTION
Uveal melanoma (UM) is the most commonly diagnosed primary intraocular cancer in adults (Singh et al., 2011) . While the disease is relatively rare in the general population, with an incidence rate of 5.1 per million, there is strong support for the role of heredity in familial UM (FUM), defined as two or more family members diagnosed with UM (Singh et al., 1996b (Singh et al., , 2011 AbdelRahman et al., 2010) . The chance of two or more first degree relatives with UM occurring in a family by chance is very low and estimated at 0.00018 (Singh et al., 1996c) . Approximately 12% of patients with UM have family history characteristics suggestive of a hereditary syndrome (AbdelRahman et al., 2010) , and evidence of an autosomal dominant mode of inheritance has been suggested (Singh et al., 1996b) . In addition, multiple reports have described the association of UM and other cancers, especially cutaneous melanoma (CM) and breast cancer (Henkind and Roth, 1971; Rednam et al., 1981; Harvey and Brinton, 1985; van Hees et al., 1998; Hemminki and Jiang, 2001; DienerWest et al., 2005b; Bergman et al., 2006) . Only a few genes that play a role in FUM have been identified, of which the BRCA-associated-protein 1 (BAP1) gene appears to have the strongest association. The frequency of BAP1 mutations in FUM is currently unknown, however, complicating genetic testing decisions in high-risk families. Furthermore, currently known genes account for only a fraction of hereditary UM, and it is likely that additional genes exist. A close analysis of families with multiple UM diagnoses can uncover shared features that may point to new cancer predisposition syndromes. Thus, the aims of this study were to estimate the prevalence of BAP1 mutations and deletions or duplications in FUM, and to demonstrate features of these families that may aid in the discovery of new genes predisposing to UM and other cancers.
MATERIALS AND METHODS

Germline Mutation Testing
Data on 25 previously unreported families with multiple individuals diagnosed with UM were included ( Table 1) . Three of these 25 families were accrued at the Cole Eye Institute at the Cleveland Clinic Foundation and the remaining families were accrued at The Ohio State University. Probands were accrued prospectively and personal and family cancer histories were collected in addition to peripheral blood. Samples were sequenced for all coding exons of BAP1 and the 5'untranslated region (UTR) according to our previously described protocol (Abdel-Rahman et al., 2011a) . The following three primer sets were used to sequence the 3'UTR (F1 ACATTCCTTC-CATCGTGCCC, R1 TGGGACACCCTACTCC-CAAC, F2 AGGTCCTTGTATCATGCCACG,  R2: GCAACCCTGTCTCTGCTACC, F3: GTT  CTAGGGCTCTTCGCCTTC and R3: AGCAA  CCACAGGAGGGTTCAT) . Sequences were aligned per the reference sequence provided by GenBank accession number NM_004656.2. All research was approved by the Institutional Review Boards at The Ohio State University and Cole Eye Institute and informed consents were obtained prior to testing. Results were combined with those from five FUM families previously reported by our group (Abdel-Rahman et al., 2011a; Pilarski et al., 2014; Cebulla et al., 2015) for a total n 5 32.
Deletion/Duplication Analysis
Deletions and duplications were assessed in 24 patients with no detected germline BAP1 sequence mutation utilizing multiplex ligationdependent probe amplification analysis (SALSA MLPA P417 BAP1 probemix, MRC-Holland) according to the manufacturer's protocol.
Literature Review
We conducted a literature review of all English language peer-reviewed articles on FUM. A PubMed search was directed with the key words "familial uveal melanoma," "familial ocular melanoma," and "familial eye melanoma". Excluding reports by our own group, a total of 28 articles describing 115 independent families with multiple UM diagnoses were identified (https://docs.google. com/spreadsheets/d/1rb0qu-4d_rPjW7qs6G1-GyfEsepWtas40QM230_4Dfg/edit?usp 5 sharing: Lynch et al., 1968; Green et al., 1978; Oosterhuis et al., 1982; Canning and Hungerford, 1988; Jay and McCartney, 1993; Young et al., 1994; Wang et al., 1996; Singh et al., 1996a Singh et al., , 1996b Singh et al., , 2000 van Hees et al., 1998; Soufir et al., 2000; Krygier et al., 2001; Hearle et al., 2003b; Kodjikian et al., 2003; BarkerGriffith and Streeten, 2004; Jonsson et al., 2005; Smith et al., 2007; Njauw et al., 2012; Wadt et al., 2012 Wadt et al., , 2014 Aoude et al., 2013; Cheung et al., 2013; Hoiom et al., 2013; Popova et al., 2013; Maerker et al., 2014; Gupta et al., 2015; Turunen et al., 2016) . Out of those, 39 families had undergone BAP1 testing; seven of these were single case reports. Single case reports were excluded from our assessment of the frequency of BAP1 mutation in familial cases to avoid introducing selection and testing bias. Thus, 32 FUM families with known BAP1 mutation status, from three published series of unselected families, were combined with our series for a meta-analysis to estimate the frequency of BAP1 mutation in FUM.
Out of the 115 reported families no genetic testing was reported in 59 probands; genetic testing results for one or more of other candidate genes (CDKN2A, CDKN2B, CDK4 and BRCA2), but not BAP1, were available in 16 additional probands (Singh et al., 1996a; Soufir et al., 2004; Hearle et al., 2003a) . No mutation was identified in any of these candidate genes. In one familial case a mutation in TP53 was suggested based on immunohistochemistry assessment (Jay and McCartney, 1993) . To evaluate the frequency of other cancers in FUM and effect of BAP1 mutation status, we combined data from our series with that from the literature. We excluded the family with putative TP53 mutation as well as those missing full reports of family histories. As such, only 53 out of the 115 families from the literature were used in the family history analysis (Lynch et al., 1968; Green et al., 1978; Oosterhuis et al., 1982; Young et al., 1994; Singh et al., 1996b Singh et al., , 2000 van Hees et al., 1998; Soufir et al., 2000; Krygier et al., 2001; Hearle et al., 2003b; Kodjikian et al., 2003; Jonsson et al., 2005; Smith et al., 2007; Njauw et al., 2012; Wadt et al., 2012 Wadt et al., , 2014 Aoude et al., 2013; Cheung et al., 2013; Hoiom et al., 2013; Popova et al., 2013; Maerker et al., 2014; Gupta et al., 2015; Turunen et al., 2016) . A two-tailed Fisher's exact test a These patients were also tested for CDKN2A, CDKN2B and CDK4. FUM011 showed a VUS in CDKN2A (chr9:21994399G > A).
was used to measure the statistical significance of variance in family cancer histories. Systematic data abstraction from the articles included family history of cancer, age of cancer diagnosis, degree of relation, and genetic testing results. Unpublished material was not consulted and supplemental material was consulted if available. Data were collated and analyzed by the authors to produce relevant results.
RESULTS
Frequency of BAP1 Alterations in FUM
The mean age of primary uveal melanoma diagnosis in probands in our cohort of 32 families was 54 years (range 18-76). Our cohort had 56% female probands. Among probands, 11/32 (34%) had a second primary cancer diagnosis in addition to UM.
Out of the 25 unreported FUM we identified two patients FUM327 and FUM340 with germline truncating mutation in BAP1 (Table 1) . Combined with our previously published families the overall BAP1 mutations frequency in our cohort was 6/32 (19% ; Table 1 ). Deletions and duplications were successfully assessed by MLPA in 24 patients, with no such alterations detected in BAP1. A variant in the 3'UTR, rs123598, was identified in 3/28 (11%) patients. The variant has been reported in the 1000 Genomes Project with a global minor allele frequency (MAF) of 0.03 (A) and Caucasian MAF of 0.06 suggesting that this is a benign variant.
The BAP1 mutation frequency in our cohort is similar to the frequency of BAP1 mutations in FUM (20-29%) found by other groups in smaller cohorts. Popova et al. found a BAP1 mutation frequency of 29% in a cohort of 14 families, while Gupta et al. and Turunen et al. found frequencies of 20% and 25% in cohorts of 10 and eight families respectively (Popova et al., 2013; Gupta et al., 2015; Turunen et al., 2016) . These previous reports sequenced the coding region of BAP1 and no reports of germline deletions or duplications were available. When our data are combined with these previous reports the frequency of BAP1 mutation in FUM is estimated to be approximately 22% (95% CI 21-23%).
Family Cancer History in FUM
Family history information collected in our prospective cohort of 32 families ranged from three to five generations. Thirteen out of all 32 families (41%) and 10 out of our 26 BAP1 mutationnegative families (38%) had a second UM diagnosis in a first-degree relative. This is approximately consistent with an autosomal dominant inheritance (Aoude et al., 2013; Cheung et al., 2013; Green et al., 1978; Gupta et al., 2015; Hearle et al., 2003a,b; Hoiom et al., 2013; Jonsson et al., 2005; Kodjikian et al., 2003; Krygier et al., 2001; Lynch et al., 1968; Maerker et al., 2014; Njauw et al., 2012; Oosterhuis et al., 1982; Popova et al., 2013; Singh et al., 2000; Singh et al., 1996b; Smith et al., 2007; Soufir et al., 2000; Turunen et al., 2016; van Hees et al., 1998; Wadt et al., 2012; Wadt et al., 2014; Young et al., 1994) . Seven studies didn't report family histories of cancer other than uveal melanoma. Only one study reported family histories of BAP1 negative familial UM patients. Mut: mutant, WT: wild type.
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pattern as has been suggested (Singh et al., 1996b) . Fifteen of the 53 FUM families in the literature with adequate family cancer history information had a BAP1 mutation, 10 families tested negative, and 28 families were untested. Table 2 summarizes the cancer family histories reported in families with and without BAP1 mutations, in our cohort and in the literature. As expected, families with BAP1 mutations have significantly higher rates of malignant mesothelioma (MMe, p 5 0.0001) and renal cell carcinoma (RCC, p 5 0.0003). Interestingly, higher rates of lung cancer approached significance (p 5 0.09) in families with BAP1 mutation while higher rates of CM, a cancer with known predisposition conferred by BAP1, did not reach statistical significance (p 5 0.2114). In FUM families without BAP1 mutation, the family history rates of MMe and RCC are significantly lower.
DISCUSSION
BAP1 has been identified as a significant UM predisposition gene. However, until now there have been few estimates as to the prevalence of germline BAP1 mutations in FUM. We estimate that BAP1 mutations are present in approximately 22% of FUM families overall, compared with 2-4% in unselected UM Turunen et al., 2016) . However, the history of other cancers in the family can significantly alter the chance of finding a BAP1 mutation. In FUM families with no other history of BAP1-associated cancers, the chance of BAP1 mutation may be as low as 8%. Conversely, the chance of BAP1 mutation in FUM families with additional family history of CM, MMe, and/or RCC can be as high as 50%. Families with multiple UM diagnoses should be referred for germline genetic testing for BAP1, even though it explains only a subset of FUM. We did not identify deletions or duplications in any of the samples tested, suggesting that large gene rearrangement is not a major contributor to germline BAP1 alterations.
There are a number of characteristics that FUM families share that point to the existence of hereditary cancer syndromes beyond BAP1. Approximately 38% of the BAP1 negative families have two UM diagnoses in first-degree relatives, consistent with autosomal dominant inheritance and suggesting that relatives are at high-risk for developing tumors. In addition, FUM families appear to have a higher cancer burden overall. For instance, the rate of second primary cancers in the probands was about 3-fold higher than in unselected UM (31% versus 10%; Diener-West et al., 2005a) . The tumor spectrum reported in the family histories is distinct between those that have germline BAP1 mutations and those that do not. Specifically, families without BAP1 mutations have lower rates of MMe and RCC as compared to those with BAP1 mutations. Comparison to rates of these cancers expected in family histories in the general population is difficult, however. It is also unclear if there is a strong association between FUM, breast cancer, and CM in these families, though this has been previously reported (Henkind and Roth, 1971; Rednam et al., 1981; Harvey and Brinton, 1985; van Hees et al., 1998; Hemminki and Jiang, 2001; Diener-West et al., 2005b; Bergman et al., 2006) . Interestingly, lung cancer may be a minor phenotype of the BAP1 syndrome, though this should be confirmed in future studies. One of the major challenges in evaluating published data on FUM is that many of the publications either listed only UM patients, UM but no other cancers or described only BAP1 positive FUM but provided no information on those with no BAP1 mutation. Establishing a registry for this rare cancer that captures such crucial information is highly warranted. Fortunately, there is a serious effort in the ocular oncology community in the US and other parts of the world to establish such a registry.
In one of the FUM families we confirmed BAP1 mutation in two family members (FUM036). In other families another family member with UM was not available for testing; however in several we confirmed BAP1 mutations in family members with other cancers. One of the mutations identified c.1717_1717delC, p.Leu573fs_3 (FUM152) was recently reported as a founder mutation in several families in North America (Carbone et al., 2015; Cebulla et al., 2015) . A synonymous rare variant rs71651686 in linkage disequilibrium with the founder mutation was also observed in the proband of FUM152 suggesting that the FUM152 is linked to the same founder mutation. We should note that we recently identified another family with the same founder mutation and the rs71651686 variant (unpublished data) and the family presented with UM and other cancers linked to the BAP1-tumor predisposition syndrome. This suggests that this founder mutation is likely underdiagnosed in the US.
Few genes have previously been implicated in predisposition for UM. The best described is BAP1, with UM risk estimated at up to 29% (Rai et al., 2016) . UM is the most frequent and earliest presenting cancer (age 16) reported in the BAP1 tumor predisposition syndrome. Interestingly, although UM was the first cancer-type associated with the gene, several other cancers were found to be associated with the syndrome upon further research (Harbour et al., 2010; Abdel-Rahman et al., 2011a; Testa et al., 2011; Wiesner et al., 2011) . As such, what first appeared as a narrow phenotype was actually a rather broad tumor predisposition syndrome. BRCA2, although primarily associated with breast and ovarian cancer risk, has been implicated in risk for UM (Sinilnikova et al., 1999; Iscovich et al., 2002; Scott et al., 2002; Hearle et al., 2003b; Liede et al., 2004) , with estimated risk between 0 and 4.8% in males (Liede et al., 2004) . The CM gene CDKN2A has also been implicated in predisposition to UM, with a single case of a pathogenic mutation in a UM patient with family history of CM (Kannengiesser et al., 2003) . Eight of our families were also tested for CDKN2A, CDKN2B and CDK4, Table 1 . One of them, FUM011, showed a variant of uncertain significance that is predicted benign (Abdel-Rahman et al., 2011b) . There has been one case report associating TP53 with UM (Jay and McCartney, 1993) , but the specific mutation was not identified. In addition, linkage studies have also identified a locus at 9q21.32 that may segregate with the UM phenotype (Jonsson et al., 2005; Bishop et al., 2009) .
In conclusion, the overall frequency of BAP1 mutation in FUM is estimated at 22%, although this can vary between 8% and 50% depending on additional family history of CM, MMe, and/or RCC. While BAP1 is the most frequent known genetic cause of FUM, it is likely that other genes exist. Future research should focus on FUM families to identify novel cancer predisposition syndromes and genes.
